'Cosmeceuticals' Spur Research But Worry FDA

Photo: John Wang ETHNOBOTANY: This Ava puhi Mohi plant will provide an ingredient for a Nu Skin cosmeticeutical to be launched in March. America's fascination with youth and physical beauty has prompted a rise in the development over recent years of "high-performance" cosmetics containing bioactive ingredients for skin damaged by the effects of sun and aging. Companies that produce personal-care products now are seeking new bioactive ingredients and new delivery system technologies. This deman

Written bySteve Bunk
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Photo: John Wang
Ava puhi
ETHNOBOTANY: This Ava puhi Mohi plant will provide an ingredient for a Nu Skin cosmeticeutical to be launched in March.
America's fascination with youth and physical beauty has prompted a rise in the development over recent years of "high-performance" cosmetics containing bioactive ingredients for skin damaged by the effects of sun and aging. Companies that produce personal-care products now are seeking new bioactive ingredients and new delivery system technologies. This demand is providing jobs for researchers in biopharmaceutical companies, but it also is causing headaches for government agencies faced with keeping track of products that often fall outside the control of safety and efficacy regulations.

"Cosmeceuticals" is the term used to describe cosmetics containing ingredients that are bioactive, exerting effects on people. The regulatory question is whether or not such ingredients make a product a drug rather than a cosmetic. Under the Food, Drug, and Cosmetic Act ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies